ALISO VIEJO, Calif., SOUTH SAN FRANCISCO, Calif. – April 12, 2012 – Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced today the launch of Fluidigm (NASDAQ:FLDM) BioMark™ HD and Access Array™ System-based genomic research services. These services provide gene expression, SNP genotyping, and sample preparation for targeted sequencing using next-generation sequencers, focused on the genomics research market.
The BioMark HD System is one of the most advanced genomic analysis instruments on the market today. It provides the sensitivity and throughput needed to study gene expression profiles down to the single-cell level, as well as high throughput SNP genotyping and digital PCR for copy number variation and rare mutation detection. The Access Array System enables high-throughput, target-enrichment for all of the major next-generation sequencing instruments and allows users to enrich multiple unique targets (such as exons) from a large number of samples, all at one time and at low cost.
Ambry Genetics offers a wide variety of genomic services that will be enhanced by the addition of Fluidigm platforms. Separately, from a regulatory standpoint Ambry can offer its other services within a CLIA setting and deliver the highest quality of data, while handling large volumes of samples with automation in place.
“For months, many of our genomics customers have been clamoring for Fluidigm technologies from single-cell gene expression to sample prep for targeted resequencing. We are ready to unleash the power of Fluidigm platforms and are anxious to offer our customers these enhanced capabilities,” said Charles Dunlop, Chief Executive Officer of Ambry Genetics. “Over the past decade, Ambry Genetics has developed one of the best reputations in the genomics industry, and a big reason is our many technology platforms and our technical abilities to apply them. Having the Fluidigm technology in house is a major step forward for us, and will continue to solidify Ambry’s reputation as a leader in this space,” Dunlop concluded.
"Ambry Genetics has a first-class reputation as an adopter of leading technologies. We at Fluidigm are thrilled that our products will be part of Ambry's portfolio of services, and we are excited about the prospect of working closely together. With the combined expertise, customer focus, and technological prowess of Fluidigm and Ambry, we are confident we will deliver a new level of value to Ambry's customers," said Gajus Worthington, President and Chief Executive Officer of Fluidigm.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, objectives, expectations and strategies for use of Fluidigm platforms by Ambry Genetics. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Risk factors that could materially affect future results are contained in Fluidigm’s filings with the Securities and Exchange Commission, including its most recent filings on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof.
About Ambry Genetics
Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory with headquarters in Aliso Viejo, Orange County, Calif. Since its founding in 1999, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly in sequencing and array services. Ambry has established a reputation for unparalleled service and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research.
To learn more about testing and services available through Ambry Genetics, visit www.ambrygen.com.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems, including eight different commercial chips, to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies. Fluidigm products are for research use only.
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo, BioMark, and Access Array are trademarks or registered trademarks of Fluidigm Corporation.
Vice President, Business Development